Insider · CIK 0001568077

Kariv Tomer

Reports to the SEC for 6 companies · FLEMINGTON, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001568077

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-06-04	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10.5K sh	—	—	10,500
2025-06-04	KROSKeros Therapeutics, Inc.A Award	Director, 10% Owner	AAward	+5,250 sh	—	—	5,250
2024-05-30	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10K sh	—	—	10,000
2023-06-06	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10K sh	—	—	10,000
2023-01-30	ELOXEloxx Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+2,859 sh	—	—	2,859
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,914 sh	$0.00	−$0.191	1,226,412
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−3,539 sh	—	—	0
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,723 sh	—	—	0
2022-11-29	KROSKeros Therapeutics, Inc. · Call Options (obligation to sell)X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,914 sh	—	—	0
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−1,723 sh	$0.00	−$0.172	1,121,045
2022-11-29	KROSKeros Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−3,539 sh	$0.00	−$0.354	2,284,612
2022-06-15	ELOXEloxx Pharmaceuticals, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-06-01	KROSKeros Therapeutics, Inc. · Stock Options (right to buy)A Award	Director, 10% Owner	AAward	+8,293 sh	—	—	8,293
2021-06-01	KROSKeros Therapeutics, Inc. · Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+8,293 sh	—	—	8,293
2021-05-19	ELOXEloxx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+1.42M sh	$1.35	+$1.92M	1,989,551
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+2.63M sh	$1.35	+$3.55M	3,679,797
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+1.28M sh	$1.35	+$1.73M	1,791,470
2021-05-13	ELOXEloxx Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+593K sh	$1.35	+$800K	616,592
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+6,000 sh	$50.00	+$300K	155,262
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+14.4K sh	$50.00	+$720K	1,228,326
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+13K sh	$50.00	+$648K	1,122,768
2020-11-17	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+26.6K sh	$50.00	+$1.33M	2,288,151
2020-05-20	ELOXEloxx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+164K sh	—	—	2,067,314
2020-04-13	KROSKeros Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−68.7K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−91.5K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+68.7K sh	—	—	68,654
2020-04-13	KROSKeros Therapeutics, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−164K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−88.5K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−82.4K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, 10% Owner	CConversion	−169K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−737K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+82.4K sh	—	—	926,796
2020-04-13	KROSKeros Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−664K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+91.5K sh	—	—	1,029,273
2020-04-13	KROSKeros Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.36M sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+169K sh	—	—	1,903,702
2020-04-13	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+43.8K sh	$16.00	+$700K	149,262
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+664K sh	—	—	844,371
2020-04-13	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+105K sh	$16.00	+$1.68M	1,213,926
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.36M sh	—	—	1,734,395
2020-04-13	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+94.5K sh	$16.00	+$1.51M	1,109,802
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+737K sh	—	—	937,735
2020-04-13	KROSKeros Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+194K sh	$16.00	+$3.11M	2,261,517
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+36.9K sh	—	—	105,512
2020-04-13	KROSKeros Therapeutics, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−36.9K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−79.7K sh	—	—	0
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+79.7K sh	—	—	1,108,926
2020-04-13	KROSKeros Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+88.5K sh	—	—	1,015,256

Recent filings

Accepted (ET)
Jun 64
Kariv Tomer0001415889-25-015977
SEC(opens sec.gov)
Jun 34
Kariv Tomer0001415889-24-015155
SEC(opens sec.gov)
Jun 84
Kariv Tomer0001209191-23-035459
SEC(opens sec.gov)
Jan 314
Kariv Tomer0001104659-23-008599
SEC(opens sec.gov)
Nov 304
Kariv Tomer0001209191-22-059051
SEC(opens sec.gov)
Jun 174
Kariv Tomer0001104659-22-072176
SEC(opens sec.gov)
Jun 34
Kariv Tomer0001209191-22-034045
SEC(opens sec.gov)
Jun 34
Kariv Tomer0001209191-21-037795
SEC(opens sec.gov)
May 204
Kariv Tomer0001415889-21-002612
SEC(opens sec.gov)
May 174
Kariv Tomer0001104659-21-067333
SEC(opens sec.gov)
Nov 194
Pontifax Late Stage GP Ltd.0001209191-20-059410
SEC(opens sec.gov)

Companies

Address

200 ROUTE 31 NORTH SUITE 104

FLEMINGTON, NJ, 08822